Skip to Main Content

Paper Details

Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
Journal of Clinical Oncology
8
2023
DIN, Dinutuximab, GM-CSF, Granulocyte-Ma Colony-Stimulating, HRNB, Irinotecan, Neuroblastoma, Patients, Relapsed High-Risk Neuroblastoma, Temozolomide, Tumors, children, dinutuximab, granulocyte-ma colony-stimulating factor, high-risk neuroblastoma, irinotecan, patients, temozolomide
Author NameAffiliation
Yimei LiChildren's Hospital of Philadelphia and University of Pennsylvania
Yimei LiUniversity of Pennsylvania
Rajen ModyUniversity of Michigan ann arbor
Rochelle BagatellChildren's Hospital of Philadelphia and University of Pennsylvania
  • 1 - 4

Datasets

Release 1.2